uric acid has been researched along with edaravone in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kamogawa, E; Sueishi, Y | 1 |
| Amaro, S; Chamorro, Á | 1 |
| Miyazaki, Y; Nagase, M; Yamamoto, Y; Yoshino, H | 1 |
| Fujisawa, A; Yamamoto, Y | 1 |
| Ando, Y; Inatomi, Y; Naganuma, M; Nakajima, M; Yonehara, T | 1 |
| Choi, YC; Han, HJ; Kim, SM; Kim, SW; Shin, HY | 1 |
| Kano, O; Nagano, Y; Nelson, S; Takahashi, F; Ushirogawa, Y; Yoneoka, T | 2 |
2 trial(s) available for uric acid and edaravone
| Article | Year |
|---|---|
Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration.
Topics: Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Biomarkers; Edaravone; Fatty Acids, Nonesterified; Female; Free Radical Scavengers; Humans; Male; Middle Aged; Oxidation-Reduction; Oxidative Stress; Peroxynitrous Acid; Ubiquinone; Uric Acid | 2016 |
Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blind Method; Edaravone; Free Radical Scavengers; Humans; Uric Acid | 2022 |
6 other study(ies) available for uric acid and edaravone
| Article | Year |
|---|---|
A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox.
Topics: Antipyrine; Chromans; Edaravone; Electron Spin Resonance Spectroscopy; Free Radical Scavengers; Free Radicals; Glutathione; Neuroprotective Agents; Uric Acid | 2014 |
Translational stroke research of the combination of thrombolysis and antioxidant therapy.
Topics: Antioxidants; Antipyrine; Biomarkers; Edaravone; Fibrinolytic Agents; Humans; Nitrogen Oxides; Oxidative Stress; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome; Uric Acid | 2011 |
Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone.
Topics: Antipyrine; Edaravone; Free Radical Scavengers; Lipid Peroxidation; Neuroprotective Agents; Oxidation-Reduction; Peroxynitrous Acid; Uric Acid | 2016 |
Associations between Uric Acid Level and 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with/without Edaravone.
Topics: Aged; Aged, 80 and over; Biomarkers; Brain Ischemia; Disability Evaluation; Edaravone; Female; Free Radical Scavengers; Humans; Hyperuricemia; Male; Middle Aged; Neuroprotective Agents; Retrospective Studies; Stroke; Time Factors; Treatment Outcome; Uric Acid | 2018 |
Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone.
Topics: Amyotrophic Lateral Sclerosis; Edaravone; Humans; Oxidative Stress; Uric Acid | 2022 |
Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19.
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials as Topic; Disease Progression; Edaravone; Free Radical Scavengers; Humans; Uric Acid | 2022 |